---
title: "Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300724579.md"
description: "Mineralys Therapeutics, Inc., a biopharmaceutical firm listed on Nasdaq under the ticker symbol MLYS, has disclosed the presentation of five abstracts at the 2026 American Heart Association (AHA) Hypertension Scientific Sessions in Arlington, VA from October 7-11. The company specializes in developing medications to address hypertension and aldosterone-related adverse effects in concurrent illnesses like chronic kidney disease, obstructive sleep apnea (OSA), and other ailments triggered by dysregulated aldosterone."
datetime: "2026-10-01T20:07:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300724579.md)
  - [en](https://longbridge.com/en/news/300724579.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300724579.md)
generator: "portal-rs"
---

# Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026

Mineralys Therapeutics, Inc., a biopharmaceutical firm listed on Nasdaq under the ticker symbol MLYS, has disclosed the presentation of five abstracts at the 2026 American Heart Association (AHA) Hypertension Scientific Sessions in Arlington, VA from October 7-11. The company specializes in developing medications to address hypertension and aldosterone-related adverse effects in concurrent illnesses like chronic kidney disease, obstructive sleep apnea (OSA), and other ailments triggered by dysregulated aldosterone.

### Related Stocks

- [MLYS.US](https://longbridge.com/en/quote/MLYS.US.md)

## Related News & Research

- [Mineralys to present lorundrostat Explore-OSA hypertension trial data at AHA Hypertension Scientific Sessions 2026](https://longbridge.com/en/news/300722541.md)
- [Will AHA Trial Data Change Mineralys Therapeutics (MLYS) Narrative](https://longbridge.com/en/news/300872529.md)
- [Mineralys Therapeutics CEO Jon Congleton disposes of $1,909,665 common shares](https://longbridge.com/en/news/300830702.md)
- [Mineralys says Transform-HTN extension data on lorundrostat set for late-breaking AHA 2026 presentation](https://longbridge.com/en/news/299938459.md)
- [Tesla's Q3 Delivery Beat Is Just the Start: Gene Munster Says TSLA Will ‘Crush Traditional Automakers’](https://longbridge.com/en/news/300968018.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**